About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Rheumatology Research Group (GRR) is focused on translational research in immunity-mediated inflammatory diseases (IMIDA), mainly in the area of rheumatology. The GRR is a multidisciplinary group made up of clinical specialists, biologists, bioinformaticians and laboratory technicians. The different research lines of the GRR emphasize the use of high-performance technologies for the study at the cellular and molecular level of the immununopathology of IMIDA, mainly chronic inflammatory arthritis and autoimmune systemic diseases.
At the clinical level, we have developed lines of research in very diverse areas of rheumatology, including chronic inflammatory arthritis (rheumatoid arthritis, spondyloarthropathies), systemic autoimmune diseases (lupus, myositis, Sjögren's syndrome), the study of musculoskeletal imaging, pediatric rheumatology (juvenile idiopathic arthritis, autoimmune systemic diseases, autoinflammatory syndromes), central sensitization syndromes and the study of bone metabolism. One of the main objectives of the GRR is the coordination of basic and clinical research to accelerate the transfer of knowledge to clinical practice and thus improve the quality of life of patients.
IP: Mireia Lopez Corbeto Collaborators: - Funding agency: Sociedad Española de Reumatología Pediátrica SERP Funding: 12000 Reference: SERPE/REUMAPED/2022/LOPEZ Duration: 30/12/2022 - 29/12/2024
IP: Carmen Espejo Ruiz Collaborators: Sara Marsal Barril, Herena Eixarch Ahufinger, Helena Borrell Paños, Maria America Lopez Lasanta Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 217313.9 Reference: CPP2021-008475 Duration: 10/02/2022 - 31/12/2025
IP: José Alegre Martin Collaborators: PATRICIA LAUNOIS OBREGÓN, Ramón Sanmartín Sentañes Funding agency: Fundación Invest. Médica Mutua Madrileña Funding: 109998 Reference: MUTUA_MADRILEÑA/2022/ALEGRE Duration: 20/07/2022 - 19/07/2025
IP: Ernesto Trallero Araguas Collaborators: Albert Selva O'Callaghan, Raul Tortosa Mendez, Albert Gil Vila, Gloria Aparicio Español, Adria Aterido Ballonga, Hugo Fernando Avalos Bogado Funding agency: Instituto de Salud Carlos III Funding: 135520 Reference: PI22/00708 Duration: 01/01/2023 - 31/12/2025
The session focused on the scientific, regulatory and clinical challenges of advanced therapy medicinal products, from preclinical research to first-in-human trials.
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
Transaction expands Formation Bio's immunology pipeline with Phase 1 ready drug candidate.
